Belumosudil for chronic graft-versus-host disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new medicine called belumosudil for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the body after a stem cell transplant. The trial compares belumosudil to the best available standard treatments to see if it works better at controlling the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have had a stem cell transplant from a donor (allogeneic).
- You have moderate to severe chronic graft-versus-host disease that has not improved after trying at least two other treatments.
- You are able to try at least one of the other standard treatments listed in the study (like ECP, MMF, or rituximab).
- You have not taken belumosudil before.
- You are generally in good health other than the graft-versus-host disease.
- You can swallow pills and absorb medicine through your stomach and intestines.
- Your kidney and liver function are within the study's required ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
This study tests a new medication called belumosudil to see how safe it is for people with chronic graft-versus-host disease (cGVHD). If you have had a stem cell transplant and still need treatment for cGVHD after trying other therapies, this trial may be an option.
This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.
This trial tests a combination of two drugs, belumosudil and rituximab, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication that can occur after a stem cell transplant. The goal is to see if this combination can control symptoms and reduce the need for steroids.
This study tests a new drug called axatilimab for children and teens with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The goal is to see if axatilimab works better than the usual care options. Participants will be randomly assigned to receive either axatilimab or one of several standard treatments.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.